MX2022008216A - Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. - Google Patents

Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.

Info

Publication number
MX2022008216A
MX2022008216A MX2022008216A MX2022008216A MX2022008216A MX 2022008216 A MX2022008216 A MX 2022008216A MX 2022008216 A MX2022008216 A MX 2022008216A MX 2022008216 A MX2022008216 A MX 2022008216A MX 2022008216 A MX2022008216 A MX 2022008216A
Authority
MX
Mexico
Prior art keywords
antagonist
lenvatinib
ilt4
salts
cancer treatment
Prior art date
Application number
MX2022008216A
Other languages
English (en)
Spanish (es)
Inventor
Rodolfo Fleury Perini
Rachel A Altura
Philip E Brandish
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022008216A publication Critical patent/MX2022008216A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022008216A 2020-01-02 2020-12-18 Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. MX2022008216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062956469P 2020-01-02 2020-01-02
PCT/US2020/065799 WO2021138079A1 (en) 2020-01-02 2020-12-18 Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof.

Publications (1)

Publication Number Publication Date
MX2022008216A true MX2022008216A (es) 2022-08-04

Family

ID=76687248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008216A MX2022008216A (es) 2020-01-02 2020-12-18 Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.

Country Status (10)

Country Link
US (1) US20230058779A1 (https=)
EP (1) EP4084794A4 (https=)
JP (1) JP2023510199A (https=)
KR (1) KR20220137007A (https=)
CN (1) CN115151258A (https=)
AU (1) AU2020416715A1 (https=)
BR (1) BR112022013143A2 (https=)
CA (1) CA3166571A1 (https=)
MX (1) MX2022008216A (https=)
WO (1) WO2021138079A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021126906A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
US20250011453A1 (en) * 2021-07-20 2025-01-09 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
CN114191547A (zh) * 2021-12-23 2022-03-18 中山大学 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
NZ733854A (en) * 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段

Also Published As

Publication number Publication date
US20230058779A1 (en) 2023-02-23
CA3166571A1 (en) 2021-07-08
BR112022013143A2 (pt) 2022-09-20
WO2021138079A1 (en) 2021-07-08
JP2023510199A (ja) 2023-03-13
EP4084794A1 (en) 2022-11-09
CN115151258A (zh) 2022-10-04
EP4084794A4 (en) 2023-10-25
KR20220137007A (ko) 2022-10-11
AU2020416715A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
EA202192553A1 (ru) Protac, расщепляющие рецептор эстрогена
JOP20210319B1 (ar) مركبات بيروليدين
WO2020033838A3 (en) Treatment of egfr-mutant cancer
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
PH12020500666A1 (en) Pladienolide compounds and their use
JOP20190209A1 (ar) مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
JP2019510807A5 (https=)
MX2023010394A (es) Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd.
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.
MX2024001892A (es) Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos.